CD79B and primary central nervous system lymphoma: Certainly, using BTKis in PCNSL, which is largely of the MCD subtype (confirmed by MYD88 and/or CD79B molecular testing), is a rational drug choice, given that the MCD subtype is highly sensitive to BTK inhibition, although some studies suggest that BTKi benefit may be agnostic to MCD variants.